South Africa Gram-Negative Infection Therapeutics Market Analysis

South Africa Gram-Negative Infection Therapeutics Market Analysis


$ 3999

The South Africa Gram-Negative Infection Therapeutics Market was valued at $96.7 Mn in 2023 and is predicted to grow at a CAGR of 7.13% from 2023 to 2030 to $156.6 Mn by 2030. Factors driving this growth encompass the high prevalence of multidrug-resistant (MDR) infections, rising awareness, and the expanding population with aging demographics. Leading companies in this market comprise Sanofi-Aventis, Eli Lilly and Company, and other notable entities.

ID: IN10ZAPH563 CATEGORY: Pharmaceuticals GEOGRAPHY: South Africa AUTHOR: Aryan Patel

Buy Now

South Africa Gram-Negative Infection Therapeutics Market Executive Summary

The South Africa Gram-Negative Infection Therapeutics Market was valued at $96.7 Mn in 2023 and is predicted to grow at a CAGR of 7.13% from 2023 to 2030 to $156.6 Mn by 2030.

Gram-negative bacterial infections pose a significant healthcare challenge due to antibiotic resistance. Species like Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa have a unique cell wall structure, making treatment challenging. They are prevalent in various healthcare settings, causing illnesses such as urinary tract infections and sepsis. Antimicrobial resistance (AMR) complicates treatment options, requiring new antibiotics, enhanced diagnostic tools, and infection control measures. Collaboration among healthcare providers, researchers, and policymakers is essential.

The mortality rate for multidrug-resistant (MDR) infections in South Africa is alarmingly high, with 34% of affected patients succumbing to the disease. The high incidence emphasizes the immediate need for effective treatment. Factors like the high prevalence of multidrug-resistant (MDR) infections, increasing awareness, and growing population and aging demographic changes increase the market growth. Limited access to diagnostic tools, inadequate healthcare infrastructure, and disparities in healthcare access restrain the market growth.

South Africa Gram Negative Infection Therapeutic Market Report 2023-2030

Market Dynamics

Market Growth Drivers

High Incidence of Multidrug-Resistant (MDR) Infections: The mortality rate for MDR infections in South Africa is significantly high, with a 34% mortality rate. The significant occurrence of MDR Gram-negative bacterial infections in South Africa, supported by the limited utilization of antibiograms for treatment decisions, underscores the pressing requirement for efficient treatments and surveillance approaches to address antimicrobial resistance. This high incidence of MDR infections drives the demand for advanced antimicrobial therapies and robust surveillance systems in the market.

Increasing Awareness: Recognizing the significance of appropriate antibiotic usage and the dangers linked with antimicrobial resistance spurs the demand for effective treatments to combat antimicrobial resistance.

Growing Population and Aging Demographics: The proportion of South Africans aged 60 and above increased from 7.6% in 2011 to 9.1% in 2021. By 2030, this percentage is expected to rise to 10.9%. The elderly population (60+) grew from 7.6% in 2002 to 9.2% in 2022. The number of older adults is projected to rise from 5.7 Mn in 2022, reaching 15.4% by 2050. South Africa's population is anticipated to reach 63 Mn by 2030, with an increasing proportion of elderly individuals more prone to infections. This demographic shift increases the demand for healthcare services, pharmaceuticals, and nutritional supplements tailored to the needs of an aging population, thereby driving market growth.

Market Restraints

Limited Access to Diagnostic Tools: The absence of diagnostic tools and laboratory facilities in South Africa restricts the prompt identification of antimicrobial resistance and appropriate antibiotic usage, impacting the treatment of Gram-negative infections. This limitation hinders the effective diagnosis and treatment of diseases, reducing the demand for advanced diagnostics and treatments that rely on accurate and timely identification of pathogens, thus acting as a market restraint.

Inadequate Healthcare Infrastructure: South Africa's insufficient healthcare infrastructure, marked by a shortage of hospital beds and medical staff, contributes to the difficulties in effectively managing Gram-negative infections. This inadequate infrastructure limits the capacity to deliver and administer necessary treatments, reducing overall healthcare service efficiency and effectiveness and restraining market growth.

Disparities in Healthcare Access: Discrepancies in healthcare access in South Africa pose a challenge, resulting in unequal access to costly new treatments, particularly for those dependent on public healthcare. This disparity impedes the ability of individuals relying on public healthcare to receive adequate treatment. As a result, this limits the customer base that can afford new and effective treatments, thereby reducing potential sales and market penetration, thus restraining market growth.

Regulatory Landscape and Reimbursement Scenario

SAHPRA (South African Health Products Regulatory Authority) is the national regulatory authority in South Africa responsible for ensuring health products' safety, quality, and efficacy, including medicines, medical devices, and complementary medicines. SAHPRA provides guidelines and regulations for the industry to follow, ensuring that products meet the required standards for safety and effectiveness. The reimbursement scenario for Gram-Negative Infection Therapeutics in South Africa involves a complex landscape with multiple payers, including the National Health Insurance (NHI) and private health insurers.

Established options are included on the NHI Essential Medicines List (EML). At the same time, newer therapeutics require a focus on cost-effectiveness, involving improved patient outcomes, reduced hospital stays, and cost-effectiveness analyses. Companies need to negotiate pricing with the National Department of Health (NDoH) and private insurers to secure coverage, with potential tiers including limited reimbursement through NHI, coverage by private insurers, or no reimbursement initially.

Factors affecting reimbursement include the severity of infection, clinical evidence, available alternatives, and price negotiations. Companies face challenges in demonstrating cost-effectiveness, navigating the complex reimbursement landscape, and negotiating pricing. Additional considerations involve out-of-pocket payments and the role of international organizations in supporting access to essential medicines.

Competitive Landscape

Key Players

Here are some of the major key players in the South Africa Gram-Negative Infection Therapeutics Market:

  • Merck & Co., Inc.
  • Baxter
  • AstraZeneca
  • GlaxoSmithKline plc (GSK)
  • Pfizer Inc.
  • Sanofi-Aventis
  • Eli Lilly and Company
  • Johnson & Johnson Services
  • AbbVie Inc.
  • Bayer AG

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

South Africa Gram-Negative Infection Therapeutics Market Segmentation

By Drug Types

  • Antibiotics
  • Combination Therapies
  • Adjunctive Therapies

By Infection Types

  • Urinary Tract Infections (UTIs)
  • Pneumonia
  • Bloodstream Infections (Bacteraemia)
  • Wound/Surgical Site Infections
  • Gastrointestinal Infections
  • Meningitis
  • Hospital-Acquired Infections (HAIs)
  • Respiratory Tract Infections (RTIs)
  • Other Infections

By Route of Administration

  • Oral
  • Parenteral (injections, intravenous)
  • Topical

By Distribution Channel

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Home Healthcare
  • Long-term Care Facilities
  • Community Health Centres

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 11 July 2024
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up